Immunovant reported financial results for the fiscal first quarter ended June 30, 2026, posting a net loss of $153.2 million, or $0.75 per share, compared to a $120.6 million loss in the prior year period. Research and development expenses increased to $142.6 million from $101.2 million due to clinical trial activities for IMVT-1402, partially offset by lower costs as batoclimab trials wind down. General and administrative expenses decreased to $17.7 million from $26.0 million. The company held $797.8 million in cash and cash equivalents at quarter-end, providing runway to the potential launch of IMVT-1402 for Graves’ disease. Clinical development timelines remain on track across six indications, with topline data expected for D2T RA and CLE in late 2026, and registrational trials for GD and MG in 2027. Immunovant is a clinical-stage immunology company developing targeted therapies for autoimmune diseases.